Scott Berry

Application of Adaptive Design Methodology in Development of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Statistical Design and Simulations

Brenda Gaydos, Zachary Skrivanek, Mary Jane Geiger, 2012, Journal of diabetes science and technology.

A Bayesian Dose-Finding Design Adapting to Efficacy and Tolerability Response

Vladimir Dragalin, Michael Krams, Scott Berry, 2012, Journal of biopharmaceutical statistics.

Potential Statistical Issues Between Designers and Regulators in Confirmatory Basket, Umbrella, and Platform Trials.

Scott Berry, S. Berry, 2020, Clinical pharmacology and therapeutics.

Use of historical control data for assessing treatment effects in clinical trials

Fang Chen, Satrajit Roychoudhury, Beat Neuenschwander, 2014, Pharmaceutical statistics.

A minimal common outcome measure set for COVID-19 clinical research

Mike Clarke, Tom Fletcher, Sabai Phyu, 2020, The Lancet Infectious Diseases.

The Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP CAP) study: rationale and design

Herman Goossens, Gernot Rohde, Paul Young, 2020 .

Adaptive platform trials: definition, design, conduct and reporting considerations

Herman Goossens, Donald A. Berry, Lorenzo Trippa, 2019, Nature Reviews Drug Discovery.

Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease

Donald A. Berry, Scott Berry, D. Berry, 2016, Alzheimer's & dementia.